Loading...

PerCP/Cyanine5.5 anti-mouse CD3ε Antibody PerCP/Cyanine5.5 anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_PerCPCyanine55_CD3e_Antibody_022219
C57BL/6 splenocytes were stained with CD45R/B220 APC and CD3e (clone 145-2C11) PerCP/Cyanine5.5 (left), or Armenian Hamster IgG PerCP/Cyanine5.5 isotype control (right).
  • 145-2C11_PerCPCyanine55_CD3e_Antibody_022219
    C57BL/6 splenocytes were stained with CD45R/B220 APC and CD3e (clone 145-2C11) PerCP/Cyanine5.5 (left), or Armenian Hamster IgG PerCP/Cyanine5.5 isotype control (right).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
100327 25 µg DKK488
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100328 100 µg DKK1408
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Duarte J, et al. 2012. J Immunol. 189:1680. PubMed
  2. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
  3. Miki H, et al. 2020. J Immunol. 204:1892. PubMed
  4. Fu A, et al. 2022. Cell. 185:1356. PubMed
  5. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  6. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  7. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  8. Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed
  9. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  10. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  11. Iwanami N, et al. 2023. Nat Commun. 14:3645. PubMed
  12. Wu SY, et al. 2022. Mol Cancer. 21:84. PubMed
  13. Feola S, et al. 2022. Front Immunol. 13:826164. PubMed
  14. Geng Z, et al. 2021. Nat Commun. 12:6584. PubMed
  15. Wu Q, et al. 2021. Cancer Commun (Lond). Online ahead of prin. PubMed
  16. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  17. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  18. Frisbee AL, et al. 2019. Nat Commun. 10:2712. PubMed
  19. Hastings AK, et al. 2019. iScience. 13:339. PubMed
  20. Fu B et al. 2017. Immunity. 47(6):1100-1113 . PubMed
  21. Girousse A et al. 2019. Cell Rep. 27(2):323-333 . PubMed
  22. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  23. Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed
  24. Engler J, et al. 2017. Proc Natl Acad Sci U S A. 114(2):E181-E190. PubMed
  25. Wu L, et al. 2022. Front Immunol. 13:860761. PubMed
  26. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  27. Helmersson S, et al. 2013. Am J Pathol. 182:1671. PubMed
  28. Di Luccia B, et al. 2020. Cell Host & Microbe. 27(6):899-908. PubMed
  29. Liao Y, et al. 2017. Virol J. 10.1186/s12985-017-0801-x. PubMed
  30. Das S, et al. 2019. Oncogene. 383316. PubMed
  31. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
  32. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  33. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  34. Bertocchi A, et al. 2021. Cancer Cell. 39(5):708-724.e11. PubMed
  35. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  36. Bennion BG, et al. 2020. Cell Reports. 31(11):107771. PubMed
  37. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  38. Katakam A, et al. 2015. Proc Natl Acad Sci U S A. 112: 14664 - 14669. PubMed
  39. Snyder LM, et al. 2022. Immunohorizons. 6:660. PubMed
  40. Abu El Maaty MA, et al. 2022. Sci Adv. 8:eabo2295. PubMed
  41. Muñoz NM, et al. 2022. Sci Rep. 12:14449. PubMed
  42. Sellau J, et al. 2016. Sci Rep. 6:28058. PubMed
  43. Härdle L, et al. 2015. Sci Rep. 5: 15112. PubMed
  44. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  45. McFarlane AJ, et al. 2017. J Allergy Clin Immunol. 140:1068. PubMed
  46. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  47. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  48. Chen Y, et al. 2022. Front Immunol. 13:835690. PubMed
  49. Uddin MJ, et al. 2022. Mucosal Immunol. 15:165. PubMed
  50. McFarland AP, et al. 2021. Immunity. 54(6):1320-1337.e4. PubMed
  51. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  52. Li H, et al. 2018. Nat Commun. 9:2830. PubMed
  53. Duan H, et al. 2021. J Clin Invest. 131:. PubMed
  54. Sibilio A, et al. 2022. iScience. 25:103790. PubMed
  55. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  56. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  57. Feng J,et al. 2017. Nat Commun. . 10.1038/s41467-017-01056-8. PubMed
  58. Su W et al. 2019. Cancer Cell. 36(2):139-155 . PubMed
  59. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
  60. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  61. Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  62. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
  63. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  64. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  65. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  66. Ko HJ, et al. 2020. Front Immunol. 1897:11. PubMed
  67. Zhu K, et al. 2022. EMBO Rep. 23:e54499. PubMed
  68. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  69. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  70. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  71. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  72. Peng V, et al. 2022. Nat Immunol. 23:619. PubMed
  73. Chen B, et al. 2021. Cell. 184:6262. PubMed
  74. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  75. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  76. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  77. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  78. Oh B, et al. 2017. Plast Reconstr Surg Glob Open. 5:e1595. PubMed
  79. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  80. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  81. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  82. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  83. Zhang B, et al. 2021. Front Neurol. 607370:12. PubMed
  84. Young K, et al. 2021. Cell Stem Cell. . PubMed
  85. Gutierrez D, et al. 2014. Diabetes. 63:3827. PubMed
  86. Thomson CA, et al. 2018. J Immunol. 201:215. PubMed
  87. Duarte J, et al. 2012. J Immunol. 189:1680. PubMed
  88. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
  89. Miki H, et al. 2020. J Immunol. 204:1892. PubMed
  90. Fu A, et al. 2022. Cell. 185:1356. PubMed
  91. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  92. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  93. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  94. Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed
  95. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  96. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  97. Iwanami N, et al. 2023. Nat Commun. 14:3645. PubMed
  98. Wu SY, et al. 2022. Mol Cancer. 21:84. PubMed
  99. Feola S, et al. 2022. Front Immunol. 13:826164. PubMed
  100. Geng Z, et al. 2021. Nat Commun. 12:6584. PubMed
  101. Wu Q, et al. 2021. Cancer Commun (Lond). Online ahead of prin. PubMed
  102. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  103. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  104. Frisbee AL, et al. 2019. Nat Commun. 10:2712. PubMed
  105. Hastings AK, et al. 2019. iScience. 13:339. PubMed
  106. Fu B et al. 2017. Immunity. 47(6):1100-1113 . PubMed
  107. Girousse A et al. 2019. Cell Rep. 27(2):323-333 . PubMed
  108. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  109. Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed
  110. Engler J, et al. 2017. Proc Natl Acad Sci U S A. 114(2):E181-E190. PubMed
  111. Wu L, et al. 2022. Front Immunol. 13:860761. PubMed
  112. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  113. Helmersson S, et al. 2013. Am J Pathol. 182:1671. PubMed
  114. Di Luccia B, et al. 2020. Cell Host & Microbe. 27(6):899-908. PubMed
  115. Liao Y, et al. 2017. Virol J. 10.1186/s12985-017-0801-x. PubMed
  116. Das S, et al. 2019. Oncogene. 383316. PubMed
  117. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
  118. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  119. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  120. Bertocchi A, et al. 2021. Cancer Cell. 39(5):708-724.e11. PubMed
  121. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  122. Bennion BG, et al. 2020. Cell Reports. 31(11):107771. PubMed
  123. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  124. Katakam A, et al. 2015. Proc Natl Acad Sci U S A. 112: 14664 - 14669. PubMed
  125. Snyder LM, et al. 2022. Immunohorizons. 6:660. PubMed
  126. Abu El Maaty MA, et al. 2022. Sci Adv. 8:eabo2295. PubMed
  127. Muñoz NM, et al. 2022. Sci Rep. 12:14449. PubMed
  128. Sellau J, et al. 2016. Sci Rep. 6:28058. PubMed
  129. Härdle L, et al. 2015. Sci Rep. 5: 15112. PubMed
  130. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  131. McFarlane AJ, et al. 2017. J Allergy Clin Immunol. 140:1068. PubMed
  132. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  133. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  134. Chen Y, et al. 2022. Front Immunol. 13:835690. PubMed
  135. Uddin MJ, et al. 2022. Mucosal Immunol. 15:165. PubMed
  136. McFarland AP, et al. 2021. Immunity. 54(6):1320-1337.e4. PubMed
  137. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  138. Li H, et al. 2018. Nat Commun. 9:2830. PubMed
  139. Duan H, et al. 2021. J Clin Invest. 131:. PubMed
  140. Sibilio A, et al. 2022. iScience. 25:103790. PubMed
  141. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  142. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  143. Feng J,et al. 2017. Nat Commun. . 10.1038/s41467-017-01056-8. PubMed
  144. Su W et al. 2019. Cancer Cell. 36(2):139-155 . PubMed
  145. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
  146. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  147. Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  148. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
  149. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  150. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  151. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  152. Ko HJ, et al. 2020. Front Immunol. 1897:11. PubMed
  153. Zhu K, et al. 2022. EMBO Rep. 23:e54499. PubMed
  154. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  155. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  156. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  157. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  158. Peng V, et al. 2022. Nat Immunol. 23:619. PubMed
  159. Chen B, et al. 2021. Cell. 184:6262. PubMed
  160. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  161. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  162. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  163. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  164. Oh B, et al. 2017. Plast Reconstr Surg Glob Open. 5:e1595. PubMed
  165. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  166. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  167. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  168. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  169. Zhang B, et al. 2021. Front Neurol. 607370:12. PubMed
  170. Young K, et al. 2021. Cell Stem Cell. . PubMed
  171. Gutierrez D, et al. 2014. Diabetes. 63:3827. PubMed
  172. Thomson CA, et al. 2018. J Immunol. 201:215. PubMed
RRID
AB_893320 (BioLegend Cat. No. 100327)
AB_893318 (BioLegend Cat. No. 100328)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD3ε Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD3ε 145-2C11 FC
PE/Dazzle™ 594 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε (Maxpar® Ready) 145-2C11 FC,CyTOF®
Brilliant Violet 510™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 605™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 711™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 785™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 750 anti-mouse CD3ε 145-2C11 FC
GoInVivo™ Purified anti-mouse CD3ε 145-2C11 FC
APC anti-mouse CD3ε 145-2C11 FC
Biotin anti-mouse CD3ε 145-2C11 FC,IHC-F
FITC anti-mouse CD3ε 145-2C11 FC
PE anti-mouse CD3ε 145-2C11 FC
PE/Cyanine5 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Alexa Fluor® 488 anti-mouse CD3ε 145-2C11 FC
Alexa Fluor® 647 anti-mouse CD3ε 145-2C11 FC,IHC-F,3D IHC
PerCP anti-mouse CD3ε 145-2C11 FC
PerCP/Cyanine5.5 anti-mouse CD3ε 145-2C11 FC
APC/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Pacific Blue™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 421™ anti-mouse CD3ε 145-2C11 FC,ICC
Ultra-LEAF™ Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Spark YG™ 593 anti-mouse CD3 145-2C11 FC
PerCP/Fire™ 780 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 650™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 750™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 810 anti-mouse CD3ε Antibody 145-2C11 FC
Spark YG™ 581 anti-mouse CD3ε (Flexi-Fluor™) 145-2C11 FC
Spark NIR™ 685 anti-mouse CD3ε (Flexi-Fluor™) Antibody 145-2C11 FC
PE/Fire™ 640 anti-mouse CD3ε 145-2C11
Go To Top Version: 4    Revision Date: 02/22/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_PerCPCyanine55_CD3e_Antibody_022219
C57BL/6 splenocytes were stained with CD45R/B220 APC and CD3e (clone 145-2C11) PerCP/Cyanine5.5 (left), or Armenian Hamster IgG PerCP/Cyanine5.5 isotype control (right).
  • 145-2C11_PerCPCyanine55_CD3e_Antibody_022219
    C57BL/6 splenocytes were stained with CD45R/B220 APC and CD3e (clone 145-2C11) PerCP/Cyanine5.5 (left), or Armenian Hamster IgG PerCP/Cyanine5.5 isotype control (right).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
100327 25 µg DKK488
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100328 100 µg DKK1408
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Duarte J, et al. 2012. J Immunol. 189:1680. PubMed
  2. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
  3. Miki H, et al. 2020. J Immunol. 204:1892. PubMed
  4. Fu A, et al. 2022. Cell. 185:1356. PubMed
  5. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  6. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  7. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  8. Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed
  9. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  10. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  11. Iwanami N, et al. 2023. Nat Commun. 14:3645. PubMed
  12. Wu SY, et al. 2022. Mol Cancer. 21:84. PubMed
  13. Feola S, et al. 2022. Front Immunol. 13:826164. PubMed
  14. Geng Z, et al. 2021. Nat Commun. 12:6584. PubMed
  15. Wu Q, et al. 2021. Cancer Commun (Lond). Online ahead of prin. PubMed
  16. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  17. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  18. Frisbee AL, et al. 2019. Nat Commun. 10:2712. PubMed
  19. Hastings AK, et al. 2019. iScience. 13:339. PubMed
  20. Fu B et al. 2017. Immunity. 47(6):1100-1113 . PubMed
  21. Girousse A et al. 2019. Cell Rep. 27(2):323-333 . PubMed
  22. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  23. Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed
  24. Engler J, et al. 2017. Proc Natl Acad Sci U S A. 114(2):E181-E190. PubMed
  25. Wu L, et al. 2022. Front Immunol. 13:860761. PubMed
  26. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  27. Helmersson S, et al. 2013. Am J Pathol. 182:1671. PubMed
  28. Di Luccia B, et al. 2020. Cell Host & Microbe. 27(6):899-908. PubMed
  29. Liao Y, et al. 2017. Virol J. 10.1186/s12985-017-0801-x. PubMed
  30. Das S, et al. 2019. Oncogene. 383316. PubMed
  31. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
  32. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  33. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  34. Bertocchi A, et al. 2021. Cancer Cell. 39(5):708-724.e11. PubMed
  35. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  36. Bennion BG, et al. 2020. Cell Reports. 31(11):107771. PubMed
  37. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  38. Katakam A, et al. 2015. Proc Natl Acad Sci U S A. 112: 14664 - 14669. PubMed
  39. Snyder LM, et al. 2022. Immunohorizons. 6:660. PubMed
  40. Abu El Maaty MA, et al. 2022. Sci Adv. 8:eabo2295. PubMed
  41. Muñoz NM, et al. 2022. Sci Rep. 12:14449. PubMed
  42. Sellau J, et al. 2016. Sci Rep. 6:28058. PubMed
  43. Härdle L, et al. 2015. Sci Rep. 5: 15112. PubMed
  44. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  45. McFarlane AJ, et al. 2017. J Allergy Clin Immunol. 140:1068. PubMed
  46. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  47. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  48. Chen Y, et al. 2022. Front Immunol. 13:835690. PubMed
  49. Uddin MJ, et al. 2022. Mucosal Immunol. 15:165. PubMed
  50. McFarland AP, et al. 2021. Immunity. 54(6):1320-1337.e4. PubMed
  51. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  52. Li H, et al. 2018. Nat Commun. 9:2830. PubMed
  53. Duan H, et al. 2021. J Clin Invest. 131:. PubMed
  54. Sibilio A, et al. 2022. iScience. 25:103790. PubMed
  55. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  56. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  57. Feng J,et al. 2017. Nat Commun. . 10.1038/s41467-017-01056-8. PubMed
  58. Su W et al. 2019. Cancer Cell. 36(2):139-155 . PubMed
  59. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
  60. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  61. Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  62. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
  63. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  64. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  65. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  66. Ko HJ, et al. 2020. Front Immunol. 1897:11. PubMed
  67. Zhu K, et al. 2022. EMBO Rep. 23:e54499. PubMed
  68. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  69. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  70. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  71. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  72. Peng V, et al. 2022. Nat Immunol. 23:619. PubMed
  73. Chen B, et al. 2021. Cell. 184:6262. PubMed
  74. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  75. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  76. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  77. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  78. Oh B, et al. 2017. Plast Reconstr Surg Glob Open. 5:e1595. PubMed
  79. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  80. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  81. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  82. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  83. Zhang B, et al. 2021. Front Neurol. 607370:12. PubMed
  84. Young K, et al. 2021. Cell Stem Cell. . PubMed
  85. Gutierrez D, et al. 2014. Diabetes. 63:3827. PubMed
  86. Thomson CA, et al. 2018. J Immunol. 201:215. PubMed
  87. Duarte J, et al. 2012. J Immunol. 189:1680. PubMed
  88. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
  89. Miki H, et al. 2020. J Immunol. 204:1892. PubMed
  90. Fu A, et al. 2022. Cell. 185:1356. PubMed
  91. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  92. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  93. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  94. Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed
  95. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  96. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  97. Iwanami N, et al. 2023. Nat Commun. 14:3645. PubMed
  98. Wu SY, et al. 2022. Mol Cancer. 21:84. PubMed
  99. Feola S, et al. 2022. Front Immunol. 13:826164. PubMed
  100. Geng Z, et al. 2021. Nat Commun. 12:6584. PubMed
  101. Wu Q, et al. 2021. Cancer Commun (Lond). Online ahead of prin. PubMed
  102. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  103. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  104. Frisbee AL, et al. 2019. Nat Commun. 10:2712. PubMed
  105. Hastings AK, et al. 2019. iScience. 13:339. PubMed
  106. Fu B et al. 2017. Immunity. 47(6):1100-1113 . PubMed
  107. Girousse A et al. 2019. Cell Rep. 27(2):323-333 . PubMed
  108. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  109. Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed
  110. Engler J, et al. 2017. Proc Natl Acad Sci U S A. 114(2):E181-E190. PubMed
  111. Wu L, et al. 2022. Front Immunol. 13:860761. PubMed
  112. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  113. Helmersson S, et al. 2013. Am J Pathol. 182:1671. PubMed
  114. Di Luccia B, et al. 2020. Cell Host & Microbe. 27(6):899-908. PubMed
  115. Liao Y, et al. 2017. Virol J. 10.1186/s12985-017-0801-x. PubMed
  116. Das S, et al. 2019. Oncogene. 383316. PubMed
  117. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
  118. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  119. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  120. Bertocchi A, et al. 2021. Cancer Cell. 39(5):708-724.e11. PubMed
  121. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  122. Bennion BG, et al. 2020. Cell Reports. 31(11):107771. PubMed
  123. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  124. Katakam A, et al. 2015. Proc Natl Acad Sci U S A. 112: 14664 - 14669. PubMed
  125. Snyder LM, et al. 2022. Immunohorizons. 6:660. PubMed
  126. Abu El Maaty MA, et al. 2022. Sci Adv. 8:eabo2295. PubMed
  127. Muñoz NM, et al. 2022. Sci Rep. 12:14449. PubMed
  128. Sellau J, et al. 2016. Sci Rep. 6:28058. PubMed
  129. Härdle L, et al. 2015. Sci Rep. 5: 15112. PubMed
  130. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  131. McFarlane AJ, et al. 2017. J Allergy Clin Immunol. 140:1068. PubMed
  132. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  133. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  134. Chen Y, et al. 2022. Front Immunol. 13:835690. PubMed
  135. Uddin MJ, et al. 2022. Mucosal Immunol. 15:165. PubMed
  136. McFarland AP, et al. 2021. Immunity. 54(6):1320-1337.e4. PubMed
  137. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  138. Li H, et al. 2018. Nat Commun. 9:2830. PubMed
  139. Duan H, et al. 2021. J Clin Invest. 131:. PubMed
  140. Sibilio A, et al. 2022. iScience. 25:103790. PubMed
  141. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  142. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  143. Feng J,et al. 2017. Nat Commun. . 10.1038/s41467-017-01056-8. PubMed
  144. Su W et al. 2019. Cancer Cell. 36(2):139-155 . PubMed
  145. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
  146. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  147. Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  148. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
  149. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  150. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  151. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  152. Ko HJ, et al. 2020. Front Immunol. 1897:11. PubMed
  153. Zhu K, et al. 2022. EMBO Rep. 23:e54499. PubMed
  154. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  155. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  156. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  157. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  158. Peng V, et al. 2022. Nat Immunol. 23:619. PubMed
  159. Chen B, et al. 2021. Cell. 184:6262. PubMed
  160. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  161. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  162. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  163. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  164. Oh B, et al. 2017. Plast Reconstr Surg Glob Open. 5:e1595. PubMed
  165. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  166. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  167. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  168. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  169. Zhang B, et al. 2021. Front Neurol. 607370:12. PubMed
  170. Young K, et al. 2021. Cell Stem Cell. . PubMed
  171. Gutierrez D, et al. 2014. Diabetes. 63:3827. PubMed
  172. Thomson CA, et al. 2018. J Immunol. 201:215. PubMed
RRID
AB_893320 (BioLegend Cat. No. 100327)
AB_893318 (BioLegend Cat. No. 100328)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD3ε Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD3ε 145-2C11 FC
PE/Dazzle™ 594 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε (Maxpar® Ready) 145-2C11 FC,CyTOF®
Brilliant Violet 510™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 605™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 711™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 785™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 750 anti-mouse CD3ε 145-2C11 FC
GoInVivo™ Purified anti-mouse CD3ε 145-2C11 FC
APC anti-mouse CD3ε 145-2C11 FC
Biotin anti-mouse CD3ε 145-2C11 FC,IHC-F
FITC anti-mouse CD3ε 145-2C11 FC
PE anti-mouse CD3ε 145-2C11 FC
PE/Cyanine5 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Alexa Fluor® 488 anti-mouse CD3ε 145-2C11 FC
Alexa Fluor® 647 anti-mouse CD3ε 145-2C11 FC,IHC-F,3D IHC
PerCP anti-mouse CD3ε 145-2C11 FC
PerCP/Cyanine5.5 anti-mouse CD3ε 145-2C11 FC
APC/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Pacific Blue™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 421™ anti-mouse CD3ε 145-2C11 FC,ICC
Ultra-LEAF™ Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Spark YG™ 593 anti-mouse CD3 145-2C11 FC
PerCP/Fire™ 780 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 650™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 750™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 810 anti-mouse CD3ε Antibody 145-2C11 FC
Spark YG™ 581 anti-mouse CD3ε (Flexi-Fluor™) 145-2C11 FC
Spark NIR™ 685 anti-mouse CD3ε (Flexi-Fluor™) Antibody 145-2C11 FC
PE/Fire™ 640 anti-mouse CD3ε 145-2C11
Go To Top Version: 4    Revision Date: 02/22/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account